Purpose The purpose of the study was to evaluate, as a pilot trial, safety and tolerability of
CAM-101 10% and 30% topical ophthalmic fibrinogen-depleted human platelet lysate (FD …

Current ocular GvHD (oGvHD) treatments are suboptimal. We investigated the safety and
efficacy of long-term continuous treatment with autologous platelet lysate (PL) drops in …

Introduction The objective of this study was to evaluate the use of autologous platelet-rich
plasma (PRP) eye drops as monotherapy for the treatment of moderate to severe cases of …

Purpose: Platelet rich plasma (PRP) is an autologous preparation that concentrates platelets
in a small volume of plasma that has been used to treat ocular surface diseases. The …

Ocular involvement of chronic graft-versus-host disease (cGVHD) is a complication that
occurs in up to 60% of patients after allogeneic hematopoietic stem cell transplantation …

Various ocular surface diseases are treated with blood-derived eye drops. Their use has
been introduced in clinical practice because of their metabolite and growth factor content …

Application of autologous serum to treat a multitude of ocular surface diseases and
conditions is a relatively new technique that has gained popularity over the past 10 years …

PURPOSE: To investigate the potential role of autologous platelet-rich plasma in promoting
healing in dormant corneal ulcers. DESIGN: Prospective, consecutive, interventional …

Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive
regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory …

Purpose Dry eye disease has public health and economic significance. Platelet-rich plasma
is rich in anti-inflammatory agents and growth factors, both beneficial for ocular surface …